ETON 19.93 ▲ 0.66% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Eton Pharmaceuticals Inc.

    NASDAQ: ETON · Real-Time Price · USD
    19.93
    0.13 (0.66%)
    At close: Oct 03, 2025, 3:59 PM
    19.80
    -0.65%
    After-hours: Oct 03, 2025, 07:11 PM EDT
    0.66%
    Bid 19.8
    Market Cap 534.47M
    Revenue (ttm) 58.18M
    Net Income (ttm) -4.13M
    EPS (ttm) -0.14
    PE Ratio (ttm) -142.36
    Forward PE 19.22
    Analyst Strong Buy
    Dividends n/a
    Ask 22
    Volume 264,993
    Avg. Volume (20D) 431,949.2
    Open 19.80
    Previous Close 19.80
    Day's Range 19.73 - 20.27
    52-Week Range 6.37 - 23.00
    Beta 1.16
    Ex-Dividend Date n/a

    About ETON

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ETON
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ETON stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Eton Pharmaceuticals Inc. is scheduled to release its earnings on Nov 11, 2025, after market closes.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 month ago
    +0%
    Eton Pharmaceuticals shares are trading higher aft... Unlock content with Pro Subscription
    2 months ago
    +9.8%
    Eton Pharmaceuticals shares are trading higher after the company announced the FDA has accepted its new drug application for ET-600.
    news image

    1 month ago · seekingalpha.com

    Eton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call Transcript

    Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David C. Krempa - Chief Business Officer James R.

    news image

    1 month ago · seekingalpha.com

    Eton Pharmaceuticals: Growth At A Reasonable Price, Or Maybe Even Better With Options

    Eton Pharmaceuticals offers GARP potential, focusing on ultra-rare disease drugs acquired at low cost, with a lean, specialized sales force and positive cash flow. My DCF model shows 80%-87% upside to...

    news image

    1 month ago · zacks.com

    Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates

    Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.12 per share a year ago.

    news image

    1 month ago · fool.com

    Eton (ETON) Q2 Revenue Jumps 108%

    Eton Pharmaceuticals (ETON), a biopharmaceutical company focused on rare diseases, posted earnings for Q2 2025 on August 7, 2025. The main highlight was a strong revenue increase from both core and re...

    news image

    2 months ago · zacks.com

    Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Eton Pharmaceuticals (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    2 months ago · seekingalpha.com

    Eton Pharma Near Term Catalysts Vanish

    Important near-term catalysts for ETON have been eliminated due to insider stock sales and a disappointing partial FDA approval for their new drug, Khindivi. Insider sales by the CEO and CBO after Q1 ...

    Add to Watchlist